An update on the state of the art of DNA vaccines

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 2, 2001, Pages 192-197

  Ulmer, J B ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antigen presenting cell; Cross priming; DNA vaccine; Plasmid DNA

Indexed keywords

DNA VACCINE; PLASMID DNA;

ANTIGEN PRESENTING CELL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; REVIEW;

ANIMALS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; TECHNOLOGY, PHARMACEUTICAL; VACCINES, DNA;

EID: 0035068943     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Direct gene transfer into mouse muscle in vivo
2. Gene-based vaccines
3. Genetic immunization is a simple method for eliciting an immune response
4. Heterologous protection against influenza by injection of DNA encoding a viral protein
5. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
6. Generation of MHC class I-restricted cytotoxic T-lymphocytes by expression of a viral protein in muscle cells: Antigen presentation by non-muscle cells
7. Muscle-specific expression of hepatitis B surface antigen: No effect on DNA-raised immune responses
8. Targeted expression of HTLV-1 envelope proteins in muscle by DNA immunization of mice
9. Induction of antiviral antibodies by DNA immunization requires neither perforin-mediated nor CD8(+)-T-cell-mediated lysis of antigen-expressing cells
10. Priming of CTL responses by DNA vaccines: Direct transfection of antigen presenting cells versus cross-priming
11. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells
12. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
13. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer
14. Immunization through dermal delivery of protein-encoding DNA: A role for migratory dendritic cells
15. In vivo priming by DNA injection occurs predominantly by antigen transfer
16. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T-cells after gene gun immunization
17. Heat shock proteins transfer peptides during antigen processing and CTL priming
18. Involvement of an ATP-dependent peptide chaperone in cross-presentation after DNA immunization
19. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered fas-mediated apoptosis
20. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice
21. WHO guidelines for assuring the quality of DNA vaccines
22. Potential DNA vaccine integration into host cell genome
23. Plasmid DNA malaria vaccine: The potential for genomic integration after intramuscular injection
24. Plasmid DNA malaria vaccine: Tissue distribution and safety studies in mice and rabbits
25. Induction of antigen-specific cytotoxic T-lymphocytes in humans by a malaria DNA vaccine
26. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial
27. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
28. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
29. Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
30. Induction of antigen-specific CD8+ T-cells, T-helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine
31. Relative potency of cellular and humoral immune responses by DNA vaccination
32. Particle-mediated nucleic acid immunization
33. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
34. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge
35. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity
36. DNA immunization against herpes simplex virus: Enhanced efficacy using a Sindbis virus-based vector
37. Enhancing immune responses using suicidal DNA vaccines
38. Cancer therapy using a self-replicating RNA vaccine
39. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo
40. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation
41. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer
42. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles
43. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses
44. Cationic microparticles: A potent delivery system for DNA vaccines
45. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle
46. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells
47. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
48. The search for a potent DNA vaccine against AIDS: The enhancement of immunogenicity by chemical and genetic adjuvants
49. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
50. Reduction of antigen expression from DNA vaccines by co-administered oligodeoxynucleotides
51. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/lg plasmid administration in rhesus monkeys
52. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
53. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
54. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
55. DNA vaccination with the human immunodeficiency virus type I SF162δV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques
56. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: Utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost
57. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
58. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
59. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigene-xpressing recombinant poxvirus
60. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
61. Enhancement of MHC class I-restricted peptide-specific T-cell induction by a DNA prime/MVA boost vaccination regime
62. Enhanced immunogenicity for CD8+ T-cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
63. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
64. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant
65. Development of a preventive vaccine for Ebola virus infection in primates